Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient

Severe adverse cutaneous drug reactions that predominantly involve the skin and mucous membranes during treatment with afatinib should alert clinicians to suspect SJS and react appropriately.